表紙:再生不良性貧血:パイプライン製品の分析
市場調査レポート
商品コード
245971

再生不良性貧血:パイプライン製品の分析

Aplastic Anemia (Hematology) - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 138 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
再生不良性貧血:パイプライン製品の分析
出版日: 2021年09月30日
発行: Global Markets Direct
ページ情報: 英文 138 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

再生不良性貧血は、末梢性汎血球減少症および骨髄形成不全という特徴をもつ骨髄損傷症です。症状は、疲労、青白い皮膚、急速あるいは不規則な心拍数、運動による息切れ、鼻血、歯肉の出血、長引く切り傷による出血、皮膚発疹、めまい、頭痛などです。危険因子は、有毒な化学物質への暴露、ガンの高線量放射線治療あるいは化学療法、特定の血液疾患、自己免疫不全、重い感染症などです。治療には免疫抑制薬と幹細胞移植などがあります。

当レポートでは、世界各国での再生不良性貧血治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

再生不良性貧血の概要

治療薬の開発

  • 再生不良性貧血向けパイプライン製品:概要
  • 企業別のパイプライン
  • 企業で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

再生不良性貧血治療薬の開発に従事している企業

  • 3SBio Inc
  • Acceleron Pharma Inc
  • Amgen Inc
  • BioLineRx Ltd
  • F. Hoffmann-La Roche Ltd
  • Gamida Cell Ltd
  • Novartis AG
  • Pluristem Therapeutics Inc
  • Regen BioPharma Inc

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

再生不良性貧血関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

List of Tables

  • Number of Products under Development for Aplastic Anemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Aplastic Anemia - Pipeline by Acceleron Pharma Inc, 2021
  • Aplastic Anemia - Pipeline by Amgen Inc, 2021
  • Aplastic Anemia - Pipeline by ASC Therapeutics Inc, 2021
  • Aplastic Anemia - Pipeline by Bellicum Pharmaceuticals Inc, 2021
  • Aplastic Anemia - Pipeline by BioLineRx Ltd, 2021
  • Aplastic Anemia - Pipeline by Cell Source Inc, 2021
  • Aplastic Anemia - Pipeline by Cellenkos Inc, 2021
  • Aplastic Anemia - Pipeline by Elixirgen Therapeutics Inc, 2021
  • Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd, 2021
  • Aplastic Anemia - Pipeline by Gamida Cell Ltd, 2021
  • Aplastic Anemia - Pipeline by Hangzhou Zede Pharmaceutical Technology Co Ltd, 2021
  • Aplastic Anemia - Pipeline by HemoGenyx Pharmaceuticals Plc, 2021
  • Aplastic Anemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
  • Aplastic Anemia - Pipeline by Novartis AG, 2021
  • Aplastic Anemia - Pipeline by Ono Pharmaceutical Co Ltd, 2021
  • Aplastic Anemia - Pipeline by Pfizer Inc, 2021
  • Aplastic Anemia - Pipeline by Regen BioPharma Inc, 2021
  • Aplastic Anemia - Pipeline by Regeneron Pharmaceuticals Inc, 2021
  • Aplastic Anemia - Dormant Projects, 2021
  • Aplastic Anemia - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Aplastic Anemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
目次
Product Code: GMDHC13083IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Drugs In Development, 2021, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 6, 2, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Aplastic Anemia - Overview
  • Aplastic Anemia - Therapeutics Development
  • Aplastic Anemia - Therapeutics Assessment
  • Aplastic Anemia - Companies Involved in Therapeutics Development
  • Aplastic Anemia - Drug Profiles
  • Aplastic Anemia - Dormant Projects
  • Aplastic Anemia - Discontinued Products
  • Aplastic Anemia - Product Development Milestones
  • Appendix